BioPharma Resources

Free tool

FAERS Monitor: Menopur

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 19, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 021663 or its brand name (Menopur, Menotropins (Fsh, Lh)). Reports on generic versions are filed under their own applications.

Reports

2,221

Serious

1,027

46% of reports

Hospitalization

598

Death reported

32

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • ovarian hyperstimulation syndrome434
  • abdominal distension198
  • drug ineffective178
  • injection site pain151
  • headache141
  • nausea133
  • abdominal pain115
  • ascites95
  • dyspnoea84
  • inappropriate schedule of drug administration81
  • fatigue73
  • abortion spontaneous69
  • vomiting61
  • maternal exposure during pregnancy54
  • dizziness51

Reports by year received

View as table
YearReports
200411
200519
200621
200745
200837
200921
201030
201136
201238
201363
201482
201580
201688
2017149
2018114
2019263
2020148
2021197
2022166
2023169
2024135
2025127
2026182

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,938 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
ovarian hyperstimulation syndromeSignal4342166.21968.7762,875
ascitesSignal9530.725.22,695
abdominal distensionSignal19818.015.83,171
abortion spontaneousSignal6916.312.9978
inappropriate schedule of drug administrationSignal8110.88.7712
maternal exposure during pregnancySignal545.74.4207
abdominal painSignal1154.73.9333
injection site painSignal1514.74.0437
headacheSignal1412.11.886
nausea1331.61.330
dyspnoea841.41.110
drug ineffective1781.31.111
vomiting611.21.02
dizziness511.00.70
fatigue730.90.71

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.